Reported 4 months ago
Goldman Sachs analysts have recommended buying European pharmaceutical stocks that focus on innovation, initiating coverage on six large-cap companies with buy ratings on AstraZeneca Plc, Novo Nordisk A/S, and Novartis AG. They are neutral on GSK Plc and Bayer AG, and have a sell rating on Roche Holding AG. The analysts highlighted Novo's potential in obesity treatments, Astra's pipeline strength, and Novartis's growth strategy. The Stoxx 600 Health Care Index has seen over a 9% increase this year, with Novo Nordisk and AstraZeneca leading the gains. AstraZeneca, for instance, plans to expand into manufacturing antibody-drug conjugates and radiopharmaceuticals with the goal of doubling sales by 2030.
Source: YAHOO